Polyrizon Ltd. (NASDAQ: PLRZ) announced it has signed agreements with two additional U.S. clinical sites, bringing the total to three contracted sites for its upcoming NASARIX clinical study. The biotech company said these sites will participate in a multi-center trial evaluating the safety, tolerability, and efficacy of the NASARIX Allergy Blocker in patients with seasonal allergic rhinitis.

The study is titled "Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients with Seasonal Allergic Rhinitis" and is designed as a multi-center trial in the United States, with up to five clinical sites expected to participate.

"We are very encouraged by the rapid expansion of our clinical site network, particularly with the addition of two highly experienced and high-enrollment centers," said Tomer Izraeli, CEO of Polyrizon. "We believe that securing the three leading sites early positions us strongly for efficient patient recruitment and timely study execution as we prepare to initiate our multi-center clinical trial."

The NASARIX investigational product is an intranasal hydrogel formulation designed to create a protective physical barrier in the nasal cavity to block airborne allergens at the point of entry. The company describes it as a non-pharmacological approach to allergy prevention.

The trial will be conducted in accordance with international Good Clinical Practice standards and applicable regulatory requirements. Polyrizon is a development-stage biotech company that specializes in developing medical device hydrogels delivered as nasal sprays.